Articles

USC research finds that the answer to getting more shots into arms is just a text message or email away.

Published in JAMA, the findings from USC and University of Wisconsin–Madison researchers suggest the policy cut the number of Medicare enrollees who weren’t filling insulin because of cost.

The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.

A fully individualized, unstructured decision-making process
will not be adequate to protect patients receiving long-term opioid
therapy.

The initiative comes with a $12.3 billion price tag — and over 10 years, the savings in health care costs will reach $18.1 billion.

One potential path for reducing Medicare Advantage (MA) overpayments from favorable selection is reforming the current administered payment approaches linking spending in fee-for-service (FFS) to MA rates.

USC Schaeffer Center senior fellow Genevieve Kanter says the risk to patient privacy posed by AI chatbots presents unique challenges.

For the first time in two decades, an Alzheimer’s drug has received full Food and Drug Administration (FDA) approval. USC Schaeffer Center experts are available to discuss this milestone and the challenges ahead.

Ultimately, health systems facing increased risk of AI chatbot breaches must decide whether to discourage clinicians’ use of this technology or embrace it.

A brief assessment in primary care can help identify patients most at risk